iHuman Stock Forecast, Price & News

-1.16 (-18.53 %)
(As of 09/16/2021 02:03 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume601 shs
Average Volume72,394 shs
Market Capitalization$271.95 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive IH News and Ratings via Email

Sign-up to receive the latest news and ratings for iHuman and its competitors with MarketBeat's FREE daily newsletter.

iHuman logo

About iHuman

iHuman Inc. provides childhood edutainment products and services to individual users, education organizations, and distributors in the People's Republic of China. The company offers interactive and self-directed learning apps, including iHuman Chinese, iHuman English, iHuman Pinyin, iHuman Magic Math, iHuman Books, and iHuman Stories. It also provides learning materials in physical and digital formats; and learning devices. The company was founded in 1996 and is based in Beijing, the People's Republic of China.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.70 out of 5 stars

Consumer Discretionary Sector

244th out of 385 stocks

Educational Services Industry

26th out of 50 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

iHuman (NYSE:IH) Frequently Asked Questions

Is iHuman a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for iHuman in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" iHuman stock.
View analyst ratings for iHuman
or view top-rated stocks.

What stocks does MarketBeat like better than iHuman?

Wall Street analysts have given iHuman a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but iHuman wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting iHuman?

iHuman saw a decrease in short interest during the month of July. As of July 30th, there was short interest totaling 99,000 shares, a decrease of 15.2% from the July 15th total of 116,700 shares. Based on an average daily trading volume, of 56,000 shares, the days-to-cover ratio is presently 1.8 days.
View iHuman's Short Interest

What guidance has iHuman issued on next quarter's earnings?

iHuman issued an update on its second quarter 2021 earnings guidance on Tuesday, July, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $33.12 million-$34.65 million.

What price target have analysts set for IH?

1 equities research analysts have issued 1-year price targets for iHuman's shares. Their forecasts range from $26.10 to $26.10. On average, they expect iHuman's share price to reach $26.10 in the next year. This suggests a possible upside of 396.2% from the stock's current price.
View analysts' price targets for iHuman
or view top-rated stocks among Wall Street analysts.

Who are iHuman's key executives?

iHuman's management team includes the following people:
  • Mr. Peng Dai, CEO & Director (Age 41)
  • Ms. Weiwei Wang, CFO & Director (Age 42)
  • Mr. Wenbin Lu, Chief Technology Officer (Age 37)

Who are some of iHuman's key competitors?

When did iHuman IPO?

(IH) raised $84 million in an initial public offering (IPO) on Friday, October 9th 2020. The company issued 7,000,000 shares at $11.00-$13.00 per share. Credit Suisse and Citigroup served as the underwriters for the IPO and Tiger Brokers, CMBI and CLSA were co-managers.

What is iHuman's stock symbol?

iHuman trades on the New York Stock Exchange (NYSE) under the ticker symbol "IH."

Who are iHuman's major shareholders?

iHuman's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Credit Suisse AG (1.78%), Morgan Stanley (1.72%), Morgan Stanley (1.72%), JPMorgan Chase & Co. (0.52%), Bank of America Corp DE (0.12%) and Citadel Advisors LLC (0.09%).

Which major investors are buying iHuman stock?

IH stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Credit Suisse AG, Bank of America Corp DE, Citadel Advisors LLC, Marshall Wace LLP, Marshall Wace LLP, and JPMorgan Chase & Co..

How do I buy shares of iHuman?

Shares of IH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is iHuman's stock price today?

One share of IH stock can currently be purchased for approximately $5.26.

How much money does iHuman make?

iHuman has a market capitalization of $280.48 million and generates $81.52 million in revenue each year.

How many employees does iHuman have?

iHuman employs 817 workers across the globe.

What is iHuman's official website?

The official website for iHuman is www.ihuman.com.

How can I contact iHuman?

The company can be reached via phone at 86-10-5780-6636 or via email at [email protected]

This page was last updated on 9/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.